Samsung Bioepis and EpisNexLab partner with G2GBio to develop long-acting obesity treatments using microsphere-based drug delivery technology, while Samsung Epis Holdings invests 20 billion won in convertible bonds as part of open innovation strategy to expand into comprehensive bio company.
#YonhapInfomax #SamsungBioepis #ObesityTreatment #G2GBio #DrugDeliveryTechnology #Semaglutide #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=110037
Samsung Bioepis, EpisNexLab Partner with G2GBio to Develop Obesity Treatment
Samsung Bioepis and EpisNexLab partner with G2GBio to develop long-acting obesity treatments using microsphere-based drug delivery technology, while Samsung Epis Holdings invests 20 billion won in convertible bonds as part of open innovation strategy to expand into comprehensive bio company.
Samsung Bioepis Reports Record Annual Revenue on Strong Biosimilar Sales
Samsung Bioepis achieved record annual revenue in 2025, driven by strong biosimilar sales in the US and Europe, while expanding its pipeline and launching new products.
Samsung Bioepis Q4 Operating Profit Plunges 60% to 29.2 Billion Won
Samsung Bioepis posts sharp 60% year-on-year drop in Q4 operating profit, signaling challenges for South Korea's biosimilar sector.
Samsung Bioepis has promoted two Executive Vice Presidents and four Senior Vice Presidents in a performance-based leadership reshuffle, highlighting expertise in clinical development, manufacturing, regulatory affairs, and business strategy.
#YonhapInfomax #SamsungBioepis #ExecutivePromotion #Biosimilars #ClinicalDevelopment #BusinessStrategy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=92338
Samsung Bioepis Promotes Two Executive Vice Presidents in Leadership Reshuffle
Samsung Bioepis has promoted two Executive Vice Presidents and four Senior Vice Presidents in a performance-based leadership reshuffle, highlighting expertise in clinical development, manufacturing, regulatory affairs, and business strategy.
South Korea's KOSPI index reversed early gains to close lower as foreign investors turned net sellers, with Samsung Bioepis plunging 28% on its relisting and sectoral moves driven by Ukraine peace talk expectations.
#YonhapInfomax #KOSPI #ForeignInvestors #SamsungBioepis #ExchangeRate #UkrainePeaceTalks #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=92177
[Stock Market-Close] Early Gains Fade on Foreign Selling—Samsung Bioepis Plunges on Relisting
South Korea's KOSPI index reversed early gains to close lower as foreign investors turned net sellers, with Samsung Bioepis plunging 28% on its relisting and sectoral moves driven by Ukraine peace talk expectations.
Samsung Bioepis has signed a partnership with China's Frontline Biopharma to jointly develop, manufacture, and commercialize next-generation antibody-drug conjugates (ADCs), securing rights to two pipeline candidates and an exclusive license for one payload, with financial terms undisclosed.
#YonhapInfomax #SamsungBioepis #FrontlineBiopharma #AntibodyDrugConjugate #ADCPartnership #OncologyPipeline #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=86432
Samsung Bioepis Signs ADC Drug Development Partnership with Chinese Biotech Firm
Samsung Bioepis has signed a partnership with China's Frontline Biopharma to jointly develop, manufacture, and commercialize next-generation antibody-drug conjugates (ADCs), securing rights to two pipeline candidates and an exclusive license for one payload, with financial terms undisclosed.
Samsung Bioepis has signed private label supply agreements with US PBM giants Express Scripts and CVS Caremark for its Stelara biosimilar, marking the first dual deal of its kind and expanding access to the US autoimmune drug market.
#YonhapInfomax #SamsungBioepis #StelaraBiosimilar #ExpressScripts #CVSCaremark #PBMSupplyDeal #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=72426Samsung Bioepis has dismissed speculation over a potential dual listing, as Samsung Biologics announces a spin-off to separate its CDMO and biosimilar businesses, emphasizing that an IPO for Bioepis is not under consideration.
#YonhapInfomax #SamsungBioepis #SamsungBiologics #SpinOff #CDMOBusiness #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=64634
Samsung Bioepis Dismisses Concerns Over Potential Dual Listing
Samsung Bioepis has dismissed speculation over a potential dual listing, as Samsung Biologics announces a spin-off to separate its CDMO and biosimilar businesses, emphasizing that an IPO for Bioepis is not under consideration.
Samsung Biologics - 'Not Considering IPO for Samsung Bioepis'
Samsung Biologics clarifies it is not currently considering an initial public offering for its subsidiary Samsung Bioepis, dispelling market speculation
Hanmi Pharm and Samsung Bioepis Sign Agreement for Osteoporosis Drug Sales
Hanmi Pharmaceutical and Samsung Bioepis partner to launch Prolia biosimilar in South Korea, aiming to provide affordable osteoporosis treatment options through joint marketing efforts.
Yonhap Infomax News